Background : Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli.
Arbekacin의 MIC 90 은 E. coli에 대해서 1 g/mL, C. freundii 에 대해서는 16 g/mL, P. aeruginosa에 대해서는 64 g/mL 으로 amikacin과 gentamicin 보다 2배 이상 낮았다 (Table 2) 
